Market News & Trends
Industry Trends: Vigilance is Critical for Future Success
Peter Soelkner says there will always be a wide variety of trends influencing our industry and we see no reason why this will not continue well into the future.
Angion Awarded $4.76-Million Department of Defense Grant for Drug Candidate
Angion Biomedica Corp. recently announced it had received a $4.76-million Department of Defense (DoD) follow-on grant for ANG-3070, its precision drug candidate for the treatment…
CytoDyn & Samsung BioLogics Enter $1-Billion Agreement
CytoDyn Inc. recently announced the execution of a comprehensive strategic agreement with Samsung BioLogics Co., Ltd. for the clinical and commercial manufacturing of leronlimab (PRO…
Moldworx Offers Unique Manufacturing Solutions to Medical Device Manufacturers
Designing solutions for medical device OEMs is the expertise of Moldworx LLC, a Gilbert, Arizona-based custom designer and builder of molds, automation solutions, and custom…
Amfora Licenses Gene-Editing Technology
Amfora recently announced it has reached a non-exclusive research and commercial license agreement with Corteva Agriscience, the Agriculture Division of DowDuPont, and the Broad Institute…
Celldex Presents Positive Interim Results From Phase 1 Study
Celldex Therapeutics, Inc. recently presented interim data from the company’s CD40 agonist program in a late-breaking poster session today at the American Association for Cancer…
Triphase Accelerator Initiates Phase 1 Clinical Trial of TRPH-222 in B-cell Lymphoma
Triphase Accelerator Corporation, a company dedicated to acquiring and developing novel therapeutics for the treatment of cancer, and Catalent, the leading global provider of advanced…
CURE Pharmaceutical to Acquire Chemistry Holdings Inc.
CURE Pharmaceutical, an innovative drug delivery and development company, recently announced that it has agreed to acquire Chemistry Holdings Inc., a formulation technology company that is developing innovative delivery systems for a variety of industries, in an all-stock transaction.
Fusion Pharmaceuticals Announces $105-Million Financing
Fusion Pharmaceuticals, a clinical-stage biopharmaceutical company developing targeted alpha-particle radiotherapeutics for treating cancer, recently announced the completion of a $105 million Series B financing led by Varian and new investor OrbiMed.
Swissfillon AG & Früh Verpackungstechnik AG Enter Strategic Collaboration
Swissfillon AG, a provider of aseptic fill and finish services to pharmaceutical and biotechnology companies, and Früh Verpackungstechnik AG, packaging manufacturer and supplier of medical and pharmaceutical contract packaging solutions, have recently entered into a partnership.
Calithera Biosciences Initiates Phase 1/2 Trial; Part of Pfizer Collaboration
Calithera Biosciences, Inc. recently announced the first patient has been treated in the Phase 1/2 open-label clinical trial of the glutaminase inhibitor telaglenastat (CB-839) in…
Race Oncology Files IND With FDA for Cancer Drug
Race Oncology Limited recently announced the US Food and Drug Administration has received its Investigational New Drug (IND) application for the company’s cancer drug Bisantrene.…
Skyrizi Approval in Japan Crucial for AbbVie as Biosimilar Competition Looms Large on Humira
At a time when pricing and reimbursement pressure is mounting on its blockbuster RA drug Humira (adalimumab) in the US and biosimilar competition looms large…
Novel Compound for Treating TBI Demonstrates Positive Results
Ischemix, Inc. recently announced significant results from a randomized, double-blinded, placebo-controlled preclinical study of its drug, CMX-2043, for the treatment of TBI. The company plans to…
Swedish Biomimetics 3000 Ltd Invents Groundbreaking Continuous Peptide Manufacturing Process
μLOT is an entirely new approach to manufacturing of therapeutic peptides, which promises to completely replace traditional large-scale batch manufacturing. The µLOT technology platform provides…
ExCellThera Announces Clearance by FDA & Health Canada for New Clinical Trials
ExCellThera Inc. recently announced its lead technology, ECT-001, will be used as part of two new clinical trials in patients with high-risk leukemia. The announcement…
Saama Closes $40-Million Financing; Driving Disruption in Clinical Analytics & Drug Development
Saama Technologies, Inc., a leading clinical data analytics platform firm, announced that it has closed a $40 million financing with Perceptive Advisors.
Autolus Therapeutics Unveils Next-Generation Technology & Pipeline
Autolus Therapeutics plc, a clinical-stage biopharmaceutical company developing next generation programmed T cell therapies for the treatment of cancer, recently presented insights into the science behind tumor defense mechanisms and the company’s novel programmed T cell therapy programs in development.
Amyris Delivers on First CBD Milestone; Collaboration Worth $300 Million
Amyris, Inc. recently announced it successfully delivered on its first milestone for its cannabinoid partner, LAVVAN, earning its first payment of $10 million, which is part of a $300-million collaboration before future royalty payments.
Cytovation Initiates Clinical Development Program for First-in-Class Agent for Tumor Immunotherapy
Cytovation AS recently announced the first patients have been treated in a Phase I clinical study with CyPep-1, a novel therapeutic agent being developed as…
